摘要
近年来,随着生活方式的改变,卵巢早衰的发病率呈明显上升趋势.以往对其均采用激素治疗,仅能够改善症状,对于卵巢功能及生育能力,无明显效果.间充质干细胞治疗是一种新型治疗方式,其依据间充质干细胞的特性(自我更新、多向分化),将其应用于特定组织损伤部位,可分化为特定类型,继而达到治疗的作用.近年来,国内外学者将间充质干细胞用于卵巢早衰的治疗中,疗效显著,但对于其作用机制尚无统一标准.SDF-1/CXCR4轴是由基质细胞衍生因子-1(SDF-1)及CXC趋化因子受体4(CXCR4)组成的偶联分子对,SDF-1及其受体CXCR4广泛分布于生物体内,参与调节多种生物学功能,对胚胎发育、卵泡发育和功能的调节有着重要作用.此文就SDF-1/CXCR4轴在间充质干细胞治疗卵巢早衰中的研究进展进行综述.
In recent years,with the change of lifestyle,the incidence rate of premature ovarian failure has shown an obvious upward trend.In the past,hormone therapy can only improve symptoms,but has no obvious effect on ovarian function and fertility.Mesenchymal stem cell therapy is a new treatment method.According to the characteristics of mesenchymal stem cells(self-renewal and multidirectional differentiation),it can be applied to specific tissue injury sites,differentiate into specific types,and then achieve the role of treatment.In recent years,scholars at home and abroad have used mesenchymal stem cells in the treatment of premature ovarian failure with remarkable curative effect,but there is no unified standard for its mechanism.SDF-1/CXCR4 axis is a coupling molecule pair composed of stromal cell-derived factor-1(SDF-1)and CXC chemokine receptor 4(CXCR4)SDF-1 and its receptor CXCR4 are widely distributed in organisms,participate in the regulation of a variety of biological functions,and play an important role in the regulation of embryonic developmentfollicular development and function.This paper reviews the research progress of SDF-1/CXCR4 axis in the treatment of premature ovarian failure by mesenchymal stem cells.
作者
钟宝山
Zhong Baoshan(Nanchang University,Nanchang,Jiangxi 330000,China)
出处
《首都食品与医药》
2022年第20期21-23,共3页
Capital Food Medicine
